The GLP is committed to full transparency. Download and review our 2019 Annual Report

We’re inching closer to a new vaccine for Lyme disease. But will the public accept it?

| | August 26, 2019
ca nid ixodes scapularis online
Image: iStock.com/Dietrerm Meyrl
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

As the threat of Lyme disease grows and fears surrounding it spread faster than the ticks that carry the infection, researchers are developing two vaccine or vaccine-like approaches to prevent this increasingly problematic disease. But don’t expect to get one soon. They are at least three to five years away from clinical use, according to their developers.

That may seem like a long time to wait… . But it’s taken researchers almost two decades to get this close — for the second time. Developers have faced an uphill battle since LYMErix, a short-lived human vaccine, was pulled from the market in 2002 amid low demand and lawsuits over potential side effects, not to mention mounting distrust in vaccines.

Related article:  Viewpoint: Here's why we should cut back on cancer screening for the elderly

As work moves forward on these two new approaches, here’s the question on many minds: Is the market ready for a new Lyme disease vaccine?

One of the new approaches is a vaccine, which works by stimulating the immune system to make antibodies that can attack Borrelia burgdorferi and other types of Borrelia, the bacteria that cause Lyme disease. The other is an injection of a single antibody.

Read full, original post: Can a New Lyme Disease Vaccine Overcome a History of Distrust and Failure?

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend